Status:
NOT_YET_RECRUITING
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
This study attempts to employ a combination therapy using rhG-CSF, IL-2, and PD-1 inhibitors, aiming to overcome the limitations of monotherapy in immunotherapy through multi-faceted immune regulation...
Detailed Description
Colorectal cancer stands as a prominent global health issue, ranking among the most prevalent malignancies worldwide. Its incidence exhibits distinct geographical variations, with higher rates observe...
Eligibility Criteria
Inclusion
- Age ≥18 years and ≤75 years
- Histologically confirmed colorectal adenocarcinoma
- pMMR (proficient mismatch repair) or MSI-L (microsatellite instability-low) or MSS (microsatellite stable)
- Synchronous liver metastases
- Achievable NED (No Evidence of Disease) status
- CRS (Clinical Risk Score) of 3-4 points
- ECOG (Eastern Cooperative Oncology Group) Performance Status score ≤ 1
Exclusion
- Recurrent colorectal cancer with active bleeding, perforation, or complex conditions requiring urgent surgery; or concurrent non-colorectal cancer malignancies.
- Patients who have previously received systemic anticancer therapy for colorectal cancer; or have been treated with PD-1, PD-L1, or CTLA-4 antibodies.
- Patients with any active autoimmune disease; known or tested positive for Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS); or a history requiring steroid or immunosuppressive drug treatment.
- Patients with interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (such as diabetes, hypertension, pulmonary fibrosis, and acute pneumonia).
- Patients who experienced any Grade 2 or higher toxicities due to prior treatments (as classified by the Common Terminology Criteria for Adverse Events \[CTCAE\] version 5), which have not resolved (excluding anemia, alopecia, and skin pigmentation changes); known or suspected history of hypersensitivity to any of the drugs used in the trial.
- Pregnant or breastfeeding women.
Key Trial Info
Start Date :
July 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 10 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06504901
Start Date
July 10 2024
End Date
July 10 2027
Last Update
July 17 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.